Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million

ORLANDO, Fla., Sept. 06, 2017, IMUN, (GLOBE NEWSWIRE)  Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing Lodonal™, its patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases and other inflammatory conditions, today announced that it has entered into an exclusive agreement with Kenya-based Omaera Pharmaceuticals, Ltd. for the sale and distribution of Lodonal™, valued at a minimum of $31 million in revenues over three years. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d02d7135-cf47-471f-9fa0-17fa3e9728a7. Under the
http://bit.ly/2wIP7ZB